Robert Figlin, MD and Debu Tripathy, MD, Discuss Breast Cancer Highlights from ESMO 2018

Friday November 2, 2018

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Debu Tripathy, MD, Professor and Chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, MD Anderson, discuss IMpassion130, SOLAR-1 and other breast cancer clinical studies presented at the meeting

Robert Figlin, MD and Barbara Burtness, MD, Discuss Head & Neck Cancer Highlights from ESMO 2018

Monday October 29, 2018

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Barbara Burtness, MD, Professor of Medicine (Medical Oncology) at the Yale University School of Medicine, discuss Keynote-048 and other H&N clinical studies presented at the meeting

Robert Figlin, MD and Bradley Monk, MD, Discuss Ovarian Cancer Highlights from ESMO 2018

Wednesday October 24, 2018

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Bradley Monk, MD, FACOG, FACS, Professor and Director of the Division of Gynecologic Oncology at Creighton University School of Medicine, discuss BRCA1+ ovarian patients, PARP inhibitors and the results of the SOLO-1 clinical trial

Robert Figlin, MD and Melissa Johnson, MD, Discuss Highlights from the 19th World Lung Conference

Friday October 5, 2018

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center speaks with Melissa Johnson, MD, Associate Director, Lung Cancer Research, Sarah Cannon Research Institute about targeted therapy, prevention, I-O in NSCLC, and I-O in SCLC.

Robert Figlin, MD, and Paul Bunn, MD, Discuss Highlights from the 19th World Lung Conference

Wednesday October 3, 2018

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center speaks with Paul Bunn, MD, Distinguished Professor, Division of Medical Oncology, University of Colorado about prevention, I-O in NSCLC, and I-O in SCLC.

Featured Videos

Sai-Hong Ignatius Ou, MD, PhD, comments on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

Howard A. "Skip" Burris III, MD, FACP, FASCO, comments on the TAILORx study from ASCO 2018

Howard (Jack) West, MD, on treatment options for patients who progress on I-O & chemotherapy